Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort Study.
暂无分享,去创建一个
David B Richardson | Stephanie M Engel | Jane A Hoppin | Matthew P Longnecker | Merete Eggesbø | Cathrine Thomsen | Azemira Sabaredzovic | Line Småstuen Haug | M. Longnecker | C. Thomsen | D. Richardson | D. Baird | J. Hoppin | J. Daniels | A. Sabaredzovic | S. Engel | G. Becher | K. Whitworth | A. Stuebe | M. Eggesbø | A. Starling | Georg Becher | G. Travlos | Ralph E. Wilson | Julie L Daniels | Ralph E Wilson | Anne P Starling | Kristina W Whitworth | Alison M Stuebe | Gregory S Travlos | Donna D Baird | L. Haug | Azemira Sabaredzovic
[1] G. Hobbs,et al. Circulating maternal perfluoroalkyl substances during pregnancy in the C8 Health Study. , 2013, Environmental science & technology.
[2] Geary W Olsen,et al. Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. , 2007, Environmental research.
[3] Harvey J Clewell,et al. Development of Pbpk Models for Pfoa and Pfos for Human Pregnancy and Lactation Life Stages , 2013, Journal of toxicology and environmental health. Part A.
[4] D. Consonni,et al. Thirty Years of Medical Surveillance in Perfluooctanoic Acid Production Workers , 2009, Journal of occupational and environmental medicine.
[5] Jeffrey H Mandel,et al. Epidemiologic Assessment of Worker Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) Concentrations and Medical Surveillance Examinations , 2003, Journal of occupational and environmental medicine.
[6] R. Collins,et al. Stability of plasma analytes after delayed separation of whole blood: implications for epidemiological studies. , 2003, International journal of epidemiology.
[7] M. Longnecker,et al. Determinants of plasma concentrations of perfluoroalkyl substances in pregnant Norwegian women. , 2013, Environment international.
[8] J. Giesy,et al. Peer Reviewed: Perfluorochemical Surfactants in the Environment , 2002 .
[9] P. Ayotte,et al. Effects of perfluorooctanesulfonate exposure on plasma lipid levels in the Inuit population of Nunavik (Northern Quebec). , 2010, Environmental research.
[10] T. Arbuckle,et al. Do perfluoroalkyl substances affect metabolic function and plasma lipids?--Analysis of the 2007-2009, Canadian Health Measures Survey (CHMS) Cycle 1. , 2013, Environmental research.
[11] Geary W Olsen,et al. Distribution of perfluorooctanesulfonate and perfluorooctanoate into human plasma lipoprotein fractions. , 2012, Toxicology letters.
[12] L. S. Haug,et al. Characterisation of human exposure pathways to perfluorinated compounds--comparing exposure estimates with biomarkers of exposure. , 2011, Environment International.
[13] E. Gratacós,et al. Atherogenic lipoprotein subfraction profile in preeclamptic women with and without high triglycerides: different pathophysiologic subsets in preeclampsia. , 2005, Metabolism: clinical and experimental.
[14] P. Ridker,et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.
[15] D. Gordon,et al. A single cholesterol measurement underestimates the risk of coronary heart disease. An empirical example from the Lipid Research Clinics Mortality Follow-up Study. , 1990, JAMA.
[16] Jan Alexander,et al. Diet and particularly seafood are major sources of perfluorinated compounds in humans. , 2010, Environment international.
[17] A. Calafat,et al. Trends in exposure to polyfluoroalkyl chemicals in the U.S. Population: 1999-2008. , 2011, Environmental science & technology.
[18] T. Woodruff,et al. Environmental Chemicals in Pregnant Women in the United States: NHANES 2003–2004 , 2011, Environmental health perspectives.
[19] D. Luthy,et al. Maternal plasma lipid concentrations in early pregnancy and risk of preeclampsia. , 2004, American journal of hypertension.
[20] J. Bar-Tana,et al. Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs. , 1995, The Journal of Biological Chemistry.
[21] H. Meltzer,et al. The biobank of the Norwegian mother and child cohort Study: A resource for the next 100 years , 2006, European Journal of Epidemiology.
[22] Roger G Perkins,et al. The Toxicology of Perfluorooctanoate , 2004, Critical reviews in toxicology.
[23] P. Magnus,et al. Cohort profile: the Norwegian Mother and Child Cohort Study (MoBa). , 2006, International journal of epidemiology.
[24] John W. Froehlich,et al. Half-Life of Serum Elimination of Perfluorooctanesulfonate,Perfluorohexanesulfonate, and Perfluorooctanoate in Retired Fluorochemical Production Workers , 2007, Environmental health perspectives.
[25] B. Koletzko,et al. Pre- and postnatal exposure to perfluorinated compounds (PFCs). , 2010, Environmental science & technology.
[26] John W Green,et al. Cross-Sectional Study of Lipids and Liver Enzymes Related to a Serum Biomarker of Exposure (ammonium perfluorooctanoate or APFO) as Part of a General Health Survey in a Cohort of Occupationally Exposed Workers , 2007, Journal of occupational and environmental medicine.
[27] C. Packard,et al. Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein. , 1997, The Journal of clinical endocrinology and metabolism.
[28] L. S. Haug,et al. A sensitive method for determination of a broad range of perfluorinated compounds in serum suitable for large-scale human biomonitoring. , 2009, Journal of chromatography. A.
[29] L. Irgens,et al. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years , 2000, Acta obstetricia et gynecologica Scandinavica.
[30] Ian T Cousins,et al. Sources, fate and transport of perfluorocarboxylates. , 2006, Environmental science & technology.
[31] Tobias Frömel,et al. Biodegradation of fluorinated alkyl substances. , 2010, Reviews of environmental contamination and toxicology.
[32] R. Luebke,et al. Immunotoxicity of Perfluorooctanoic Acid and Perfluorooctane Sulfonate and the Role of Peroxisome Proliferator-Activated Receptor Alpha , 2009, Critical reviews in toxicology.
[33] A. IJzerman,et al. Nicotinic acid receptor subtypes and their ligands , 2007, Medicinal research reviews.
[34] Anders Bignert,et al. Perfluorinated alkyl acids in blood serum from primiparous women in Sweden: serial sampling during pregnancy and nursing, and temporal trends 1996-2010. , 2012, Environmental science & technology.
[35] M. A. Mohd,et al. Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. , 2004, Environmental science & technology.
[36] Per Magnus,et al. Self-selection and bias in a large prospective pregnancy cohort in Norway. , 2009, Paediatric and perinatal epidemiology.
[37] M. Aurell,et al. Serum lipids and lipoproteins in human pregnancy. , 1966, Clinica chimica acta; international journal of clinical chemistry.
[38] C. Lau,et al. Activation of mouse and human peroxisome proliferator-activated receptor-alpha (PPARα) by perfluoroalkyl acids (PFAAs): further investigation of C4-C12 compounds. , 2012, Reproductive toxicology.
[39] Jane A Hoppin,et al. Perfluorinated Compounds and Subfecundity in Pregnant Women , 2012, Epidemiology.
[40] T. Webster,et al. Exposure to Polyfluoroalkyl Chemicals and Cholesterol, Body Weight, and Insulin Resistance in the General U.S. Population , 2009, Environmental health perspectives.
[41] J. Klenk,et al. Analyses of Case–Control Data for Additional Outcomes , 2007, Epidemiology.
[42] C. Lau,et al. Perfluoroalkyl acids: a review of monitoring and toxicological findings. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[43] C. Packard,et al. Lipoprotein Subfraction Concentrations in Preeclampsia: Pathogenic Parallels to Atherosclerosis , 1997, Obstetrics and gynecology.
[44] L. Wallentin,et al. Plasma Lipoproteins Including High Density Lipoprotein Subfractions During Normal Pregnancy , 1985, Obstetrics and gynecology.
[45] Jiayin Dai,et al. Association of perfluorooctanoic acid with HDL cholesterol and circulating miR-26b and miR-199-3p in workers of a fluorochemical plant and nearby residents. , 2012, Environmental science & technology.
[46] Kyle Steenland,et al. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. , 2009, American journal of epidemiology.
[47] Jørn Olsen,et al. Perfluorinated Chemicals and Fetal Growth: A Study within the Danish National Birth Cohort , 2007, Environmental health perspectives.
[48] A. Ciampi,et al. Effects of exposure measurement error when an exposure variable is constrained by a lower limit. , 2003, American journal of epidemiology.
[49] D. Savitz,et al. Perfluorooctanoic Acid Exposure and Pregnancy Outcome in a Highly Exposed Community , 2012, Epidemiology.
[50] C. Lau,et al. Perfluorooctanoic acid induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[51] W. Piechota,et al. Reference ranges of lipids and apolipoproteins in pregnancy. , 1992, European journal of obstetrics, gynecology, and reproductive biology.
[52] S. Haeri,et al. Maternal serum dyslipidemia occurs early in pregnancy in women with mild but not severe preeclampsia. , 2008, American journal of obstetrics and gynecology.
[53] A. Calafat,et al. Effect of temperature and duration of storage on the stability of polyfluoroalkyl chemicals in human serum. , 2013, Chemosphere.
[54] R. Mensink,et al. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. , 2003, The American journal of clinical nutrition.
[55] Z. Akkuş,et al. Potential atherogenic roles of lipids, lipoprotein(a) and lipid peroxidation in preeclampsia. , 2005, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[56] D. Savitz,et al. Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project. , 2010, Archives of pediatrics & adolescent medicine.
[57] B. Nordestgaard,et al. Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction , 2008, Circulation.
[58] Cathrine Thomsen,et al. Time trends and the influence of age and gender on serum concentrations of perfluorinated compounds in archived human samples. , 2009, Environmental science & technology.
[59] Hermann Fromme,et al. Perfluorinated compounds--exposure assessment for the general population in Western countries. , 2009, International journal of hygiene and environmental health.
[60] K. Vollebregt,et al. Maternal lipid profile during early pregnancy and pregnancy complications and outcomes: the ABCD study. , 2012, The Journal of clinical endocrinology and metabolism.
[61] A. Calafat,et al. Rate of Decline in Serum PFOA Concentrations after Granular Activated Carbon Filtration at Two Public Water Systems in Ohio and West Virginia , 2009, Environmental health perspectives.
[62] Jonathan P. Benskin,et al. Exceptionally high serum concentrations of perfluorohexanesulfonate in a Canadian family are linked to home carpet treatment applications. , 2012, Environmental science & technology.
[63] C. Lau,et al. Developmental toxicity of perfluorooctane sulfonate (PFOS) is not dependent on expression of peroxisome proliferator activated receptor-alpha (PPAR alpha) in the mouse. , 2009, Reproductive toxicology.